SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX)

NEW YORK, Aug. 10, 2016

The investigation concerns whether Nymox and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On August 10, 2016, Seeking Alpha issued an article entitled "Nymox: This Offshore 'Biotech' Promotion Will Go To Zero (Yes, Zero)", in which it stated that Nymox's administration is constantly deceiving shareholders about Nymox's projections while "aggressively dump[ing] stock without timely SEC disclosure."  Following this news, Nymox stock dropped as much as $1.47 per share, or 47.27%, to $1.64 during intraday trading on August 10, 2016.

If you purchased Nymox shares or if you are aware of any facts relating to this investigation, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/nymx.  You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com